DOCSLIB.ORG

Progress in Retinal and Eye Research 73 (2019) 100764

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progress in Retinal and Eye Research 73 (2019) 100764 Progress in Retinal and Eye Research 73 (2019) 100764 Contents lists available at ScienceDirect Progress in Retinal and Eye Research journal homepage: www.elsevier.com/locate/preteyeres Conservative management of retinoblastoma: Challenging orthodoxy T without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity” ∗ Francis L. Muniera, , Maja Beck-Popovicb, Guillermo L. Chantadac,d,e, David Cobrinikf,g, Tero T. Kiveläh, Dietmar Lohmanni, Philippe Maederj, Annette C. Mollk, Angel Montero Carcabosod,e, Alexandre Moulina, Paula Schaiquevichl,m, Ciara Bergina, Paul J. Dysonn, Susan Houghtona, Francesco Puccinellio, Yvan Vialp, Marie-Claire Gaillarda, Christina Stathopoulosa a Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Lausanne, Switzerland b Unit of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland c Hemato-Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina d Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona, Spain e Institut de Recerca Sant Joan de Deu, Barcelona, Spain f The Vision Center and The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA g USC Roski Eye Institute, Department of Biochemistry & Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA h Department of Ophthalmology, Ocular Oncology and Pediatric Ophthalmology Services, Helsinki University Hospital, Helsinki, Finland i Eye Oncogenetics Research Group, Institute of Human Genetics, University Hospital Essen, Essen, Germany j Unit of Neuroradiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland k UMC, Vrije Universiteit Amsterdam, Department of Ophthalmology, Cancer Center Amsterdam, Amsterdam, Netherlands l Unit of Clinical Pharmacokinetics, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina m National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina n Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland o Interventional Neuroradiology Unit, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland p Materno-Fetal Medicine Unit, Woman-Mother-Child Department, University Hospital of Lausanne, Switzerland ARTICLE INFO ABSTRACT Dedicated to A. Linn Murphree my paragon and Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with mentor, and to Akihiro Kaneko who pioneered ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first modern targeted chemotherapy of intraocular successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage retinoblastoma attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a “state of metastatic grace” never to be violated. Keywords: Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of Retinoblastoma improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic Treatment Intra-arterial chemotherapy chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 Intravitreal chemotherapy years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely Intracameral chemotherapy intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, de- Complication finitive eradication of radiotherapy and reduction of systemic chemotherapy. Metastasis Here we intend to review the relevant knowledge susceptible to improve the conservative management of retino- Liquid biopsy blastoma in compliance with the “state of metastatic grace”, with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality. ∗ Corresponding author. Head of Ocular Oncology, Pathology and Genetics, Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Avenue de France 15, 1000, Lausanne 7, Vaud, Switzerland. E-mail address: [email protected] (F.L. Munier). https://doi.org/10.1016/j.preteyeres.2019.05.005 Received 17 February 2019; Received in revised form 25 May 2019; Accepted 29 May 2019 Available online 05 June 2019 1350-9462/ © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/). F.L. Munier, et al. Progress in Retinal and Eye Research 73 (2019) 100764 1. Introduction chemotherapy using intra-arterial and intravitreal drug delivery was pioneered in Japan by Akihiro Kaneko already 30 years ago (Kaneko Retinoblastoma is the archetype of developmental tumors and is and Takayama, 1990; Yamane et al., 2004). In 2008, the technique of responsible for 17% of neonatal (Halperin, 2000), 13% of infantile intra-arterial chemotherapy, revisited by Abramson (Abramson et al., (Vasilatou-Kosmidis, 2003), 6% and 3% of all pediatric cancers under 2008), became rapidly adopted and proved its efficacy to control retinal age 5 and 15 years, respectively (Broaddus et al., 2009; Group et al., and subretinal tumors, but not vitreous seeds. The latter fully surren- 2013). Left untreated, this malignancy is rapidly recognizable as a dered only to intravitreal chemotherapy, which became available in protruding mass. Within the limitations of retrospective diagnosis 2012 following the description of a safety-enhanced injection technique (Kivela and Polkunen, 2003), it is thus not surprising to find retino- (Munier et al., 2012a). Aqueous seeding, the very last intra-ocular blastoma already mentioned in the medical literature at the turn of the sanctuary to resist virtually all available treatment modalities, became XVIth and XVIIth centuries by Pawius in the Netherlands (Pawius, 1657) manageable only since 2015 with the description of a technique and Hildanus in Switzerland (Hildanus, 1682) respectively. According adapted to safely inject into the anterior and posterior chambers to the Hippocratic theory of four humors still in use at that time, ocular (Munier et al., 2015), now successfully implemented in the current tumors were thought to result from a causal chain, of which the pa- management of aqueous disease (Munier et al., 2017a, 2018). To date, tient's constitution and hygiene was the first link (causa primitiva), the appropriate combination of all these modalities has enabled un- triggering black bile overflow (causa antecedens) pouring into the eye precedented eye survival rates, even for advanced retinoblastoma, after its transfer to the brain (causa coniuncta)(Koelbing, 1954). The contributing at the same time to the eradication of external beam ir- advocated treatment was a combination of poultice, leech and purge to radiation in the treatment of intraocular retinoblastoma without jeo- eliminate the flood of melancholic humor. This approach was sup- pardizing patient survival. planted by enucleation, made possible by the advent of anesthesia in th the middle of the XIX century, leading to the first success in terms of 2. Epidemiology patient survival. This surgical period lasted more than 50 years, until the radiosensitivity of retinoblastoma was discovered by Hilgartner in Retinoblastoma is a cancer of early childhood, habitually described 1903 (Hilgartner, 1903), allowing for the first time a conservative as a rare tumor. Statistical evidence, however, suggests that it is likely (globe-preserving) management of the disease. Since then, and for the the most common eye cancer worldwide (Kivela, 2009). As a devel- next 90 years, external beam irradiation became the first line treatment, opmental cancer, its incidence is highly dependent on age (Table 1), complemented by focal therapeutic modalities such as cryotherapy, and therefore difficult to establish. To date, the most stable estimates xenon photocoagulation and brachytherapy for less advanced diseased are derived by assigning incident retinoblastomas to the year the pa- eyes. In 1996, following the recognition of a radio-induced neoplasm tient was born, a method known as birth cohort analysis (Li et al., 2016; predisposition in germline carriers, chemoreduction replaced radio- Park et al., 2014; Seregard et al., 2004). therapy, which use was relegated to treat chemo-resistant disease in only eyes as an alternative to enucleation. The introduction of this 2.1. Incidence whole-body therapy failed, however, to improve eye preservation in advanced disease, while exposing children to systemic toxicity. This The incidence of retinoblastoma depends on the size of the popu- was explained by the pharmacokinetics of the perfused drugs not lation and the birth rate (Kivela, 2009). Around 7980 retinoblastomas reaching tumoricidal concentrations in the
Load more

Recommended publications
  • The Role of Combined Therapy in the Treatment of Retinopathy and Optic Neuropathy Due to Radiotherapy in the Uveal Melanoma
    Published online: 2020-01-16 THIEME Original Article 1 The Role of Combined Therapy in the Treatment of Retinopathy and Optic Neuropathy Due to Radiotherapy in the Uveal Melanoma Yasemin Benderli Cihan1 1Department of Radiation Oncology, Kayseri Education and Address for correspondence Yasemin Benderli Cihan, MD, Department Research Hospital, Kayseri, Turkey of Radiation Oncology, Kayseri Education and Research Hospital, Sanayi District, Ataturk Boulevard, Hastane Street, No 78, 38010 Kocasinan, Kayseri, Turkey (e-mail: [email protected]). Asian J Oncol 2020;6:1–2 Abstract Introduction Uveal melanoma has a relatively low incidence. Transpupillary thermo- therapy (TTT), hypofractioned stereotactic radiotherapy (RT), stereotactic radiosur- gery, plaque brachytherapy, charged particle radiation therapy, local tumor resection, enucleation, and exantation are applied in the treatment. Methods The importance given to radiotherapy has increased to get more satisfac- tory results while treating the patient. However, it is the treatment of radiation reti- nopathy and optic neuropathy from complications. Results Radiation retinopathy and optic neuropathy are the most important compli- Keywords cations related to radiotherapy in the treatment of uveal melanoma. In recent years, ► uveal melanoma many studies have been performed on the treatment of radiation retinopathy and ► radiotherapy optic neuropathy. ► retinopathy Conclusion The consecutive use of triamcinolone in combination with anti-VEGF ► optic neuropathy supports that it may be a future therapeutic agent in the treatment of complications. Introduction was found to be 81.6%.2 The 2-, 5-, and 10-year metastasis rates were reported to be 10%, 25%, and 34%, respectively, regardless Uveal melanoma is the most common primary intraocular of tumor size.3 tumor in adults.
    [Show full text]
  • Retinoblastoma Major Review with Updates on Middle East Management Protocols
    Saudi Journal of Ophthalmology (2012) 26, 163–175 Ophthalmic Pathology Update Retinoblastoma major review with updates on Middle East management protocols ⇑ Ihab Saad Othman, MD, FRCS Abstract Many advances in the field of management of retinoblastoma emerged in the past few years. Patterns of presentation of retino- blastoma in the Middle East region differ from Western community. The use of enucleation as a radical method of eradicating advanced disease is not easily accepted by patient’s family. We still do see stage E, failed or resistant retinoblastoma and advanced extraocular disease ensues as a result of delayed enucleation decision. In this review, we discuss updates in management of retinoblastoma with its implication on patients in our part of the world. Identifying clinical and high risk characteristics is impor- tant prognostically and are discussed for further management of retinoblastoma cases. Keywords: Retinoblastoma, Staging, Classification, Histopathology, Middle East Ó 2012 Saudi Ophthalmological Society, King Saud University. All rights reserved. http://dx.doi.org/10.1016/j.sjopt.2012.03.002 Introduction cases is 100–120 cases/year.3 In a recent report from Jordan, the mean age-adjusted incidence of retinoblastoma was 9.32 Retinoblastoma is the commonest primary ocular malig- cases per million children per year for children aged 0– nancy of childhood originating from primitive retinoblasts 5 years.4 Retinoblastoma constituted 4.8% of childhood can- with tendency towards cone differentiation. Retinoblasts cer treated over 10 years at the National Cancer Institute in arise from the inner neuroepithelial layers of the embryonic Sudan and presented in an advanced stage in 16 out of 25 re- optic cup.1 The incidence of retinoblastoma ranges from 1/ ported cases.5 15,000 to 1/20,000 live births with an annual incidence in chil- dren younger than 5 years of 10.9/million.
    [Show full text]
  • Case Report Comment
    Sir, Visual preservation 18 years after cobalt plaque treatment of choroidal melanoma Brachytherapy using a radioactive plaque is a common method of treating choroidal melanoma today.l Vision can often be retained following brachytherapy for peripheral melanomas, but most patients lose considerable vision when the tumour is located in the macular region.2 We report a case of choroidal melanoma with a margin within 3 mm from the foveola in which the patient retained excellent vision 18 years after treatment with a cobalt-60 plaque. Case report Fig. 2. Wide-angle fundus photograph showing the tumour. The In March 1980, a 51-year-old man was referred for a retinal detachment is not easily visualised in the photograph. choroidal melanoma. His visual acuity was 20/20 in each eye and intraocular pressures were normal. In his ultrasonography. There was a distinct margin between right eye was a dome-shaped, pigmented choroidal the irradiated tumour and the normal foveal area mass (Figs. 1-3) 12 X 11 mm basally and 6 mm in (Fig. 6). For 18 years the vision has remained 20/20 and thickness as measured by estimation and there is no tumour recurrence or radiation retinopathy ultrasonography (Fig. 4). The posterior margin of the (Figs. 5, 6). tumour was 3 mm temporal to the foveola (Fig. 3). The patient elected treatment with a radioactive plaque, which was done by our standard technique. 1 A Comment dose of 35 000 cGy was delivered to the tumour base and macular area and 10 000 cGy to the tumour apex. Six When a melanoma is in the macular area (tumour months after treatment the tumour was 2 mm in margin within 3 mm of the foveola) most patients thickness by ultrasonography and 1 year later it was treated with plaque or charged particle radiotherapy entirely flat on ophthalmoscopy (Fig.
    [Show full text]
  • Diagnosis, and Treatment of Retinoblastoma
    British3'ournal ofOphthalmology 1993; 77: 805-812 805 PERSPECTIVE Br J Ophthalmol: first published as 10.1136/bjo.77.12.805 on 1 December 1993. Downloaded from Applications ofmonoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma John F Tarlton, D L Easty In Europe and North America, retinoblastoma has a reported derived cell lines fused with RB1 competent cells.2' Reversal incidence ranging from 1 in 14 000 to 1 in 36 000 live births'-5 of malignancy has also been reported in cell lines transfected and is the most common ocular malignancy affecting children with functional BR1 gene constructs. Recently, however, and infants. Early diagnosis allows the application of a these results have been challenged by other researchers who number of therapies directed at localised disease, including have found incomplete reversal of malignancy in retino- external beam and plaque radiotherapy, cryotherapy, and blastoma cell lines,22 although such effects may be artefacts photocoagulation, although the principal treatment account- resulting from additional genetic changes having occurred in ing for the high cure rate ofaround 90% is enucleation, which cells adapting to tissue culture environments. The impor- is still carried out in over halfofall cases. The justification for tance of RB1 in malignant transformation has also been such radical therapy is the poor prognosis once the tumour demonstrated by inactivating its product by association with escapes the eye, and the high mortality from metastases.6 virus proteins such as adenovirus EIA,23 SV40 large T In the developing countries ofAfrica and Asia the picture is antigen24 and papillomavirus E7 oncoprotein,2" both by different.
    [Show full text]
  • Radiotherapy of Conjunctival Melanoma: Role and Challenges of Brachytherapy, Photon-Beam and Protontherapy
    applied sciences Review Radiotherapy of Conjunctival Melanoma: Role and Challenges of Brachytherapy, Photon-Beam and Protontherapy Corrado Spatola 1,2, Rocco Luca Emanuele Liardo 2, Roberto Milazzotto 2 , Luigi Raffaele 2, Vincenzo Salamone 2, Antonio Basile 1,2, Pietro Valerio Foti 1,2, Stefano Palmucci 1,2 , Giuseppe Antonio Pablo Cirrone 3, Giacomo Cuttone 3, Andrea Russo 4 , Teresio Avitabile 4, Michele Reibaldi 5 , Antonio Longo 4, Giuseppe Broggi 1 , Vincenza Bonfiglio 6, Rosario Caltabiano 1 , Stefano Pergolizzi 7 and Floriana Arena 7,* 1 Dipartimento di Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, Università di Catania, 95125 Catania, Italy; [email protected] (C.S.); [email protected] (A.B.); [email protected] (P.V.F.); [email protected] (S.P.); [email protected] (G.B.); [email protected] (R.C.) 2 UO Radiodiagnostica e Radioterapia Oncologica AOU Policlinico-S.Marco Catania, 95125 Catania, Italy; [email protected] (R.L.E.L.); [email protected] (R.M.); raff[email protected] (L.R.); [email protected] (V.S.) 3 Istituto Nazionale di Fisica Nucleare-LNS Catania, 95125 Catania, Italy; [email protected] (G.A.P.C.); [email protected] (G.C.) 4 Dipartimento di Chirurgia Generale e Specialità Medico-Chirurgiche, Università di Catania, 95125 Catania, Italy; [email protected] (A.R.); [email protected] (T.A.); [email protected] (A.L.) 5 Dipartimento di Oftalmologia, Università di Torino, 10124 Torino, Italy; [email protected] 6 Dipartimento
    [Show full text]
  • Radiation Therapy Coding
    Ed 21:01 Radiation March 2021 Missouri Cancer Registry and Research Center Therapy 2021 Show-Me-Tips Coding...Abstracting...Education… Radiation Therapy Coding Radiation Delivery Systems/Approaches and Coding LINEAR ACCELERATOR - Linac If the radiation treatment summary refers to beam energies, such as: • 6X or 6MV, 10X or 10MV • 12X or 12MV, 15X or 15MV Then the treatment modality will always be 02, external beam, photons (a Linac was used to deliver the EBRT treatment) If radiation treatment summary refers to treatment delivery as: • E, eboost, MeV or “en face” Code the treatment modality 04, external beam, electrons (a Linac can also deliver electron therapy) IORT Delivery Technology & Coding IORT FOR BREAST CANCER, Volume: 41 - Partial Breast. Lymph Nodes are not Targeted! Equipment RT Delivery Modality Planning Comments Method Technique Zeiss Intrabeam 50 kVp Linac 02-Photons 02: Low energy x-ray/ Isotope-free. No photon therapy radioactive source used XOFT Axxent 50 kVp Linac 02-Photons 02: Low energy x-ray/ Isotope-free. No photon therapy radioactive source used LIAC 10/12 by Electron 04-Electrons In most cases, Max energy: 10 MeV, Sordina IORT accelerator 04-3D conformal 12 MeV NOVAC by Electron 04-Electrons In most cases, Check with Rad Onc for Sordina IORT accelerator 04-3D conformal planning technique Mobetron Electron 04-Electrons In most cases, Energies: 6, 9, 12 MeV accelerator 04-3D conformal Strut Assisted Ir-192 Sources 09-Brachy, 88 - NA Accelerated partial breast Volume (HDR) Intracavitary HDR irradiation (PBI) Implant
    [Show full text]
  • Optic Nerve: Developmental Anomalies and Common Tumors
    DOI: 10.5772/intechopen.80326 ProvisionalChapter chapter 3 Optic Nerve: Developmental Anomalies and Common Tumors HindHind Alkatan, Alkatan, Daniah AlshowaeirDaniah Alshowaeir and TariqTariq Alzahem Alzahem Additional information is available at the end of the chapter http://dx.doi.org/10.5772/intechopen.80326 Abstract The optic nerve, also known as the second cranial nerve, is composed of axons that trans- mit visual information from the neurosensory retina to the visual cortex. There are mul- tiple pathologies that can affect the human optic nerve. Congenital anomalies of the optic nerve include myelinated nerve fibers, morning glory syndrome, optic nerve choristoma, optic nerve coloboma, optic nerve hypoplasia and aplasia, and others. Tumors that can affect the optic nerve (ON) may occur primarily from within the nerve itself, from the sur- rounding optic nerve sheath (ONS), or secondarily spreading to the nerve from a distant site. They include optic pathway glioma, medulloepithelioma, oligodendroglioma, optic nerve sheath meningioma, and others. Here in this chapter, we will review the optic nerve anatomy, embryology, and physiology in addition to assessment of optic nerve function. Moreover, the clinical features, imaging findings, pathology, and treatment options of the most common and some rare congenital anomalies and primary tumors of the ON and sheath will be reviewed. Keywords: myelinated nerve fibers, morning glory syndrome, optic nerve choristoma, optic nerve coloboma, optic nerve hypoplasia, aplasia, optic nerve tumor, glioma, meningioma, ganglioglioma, medulloepithelioma, hemangioblastoma, oligodendroglioma 1. Introduction Visual perception occurs when light stimulus in the surrounding environment converts to nerve impulses at the level of photoreceptors, which then reach the brain to be processed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156881 A1 Stokes (43) Pub
    US 20090156881A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156881 A1 Stokes (43) Pub. Date: Jun. 18, 2009 (54) CONVERGENT WELL IRRADIATING Publication Classification PLAOUE FOR CHOROIDAL MELANOMA (51) Int. Cl. (76) Inventor: John P. Stokes, San Antonio, TX A6M 36/12 (2006.01) (US) A6DF 9/00 (2006.01) (52) U.S. Cl. ............................................................ 6OOf7 Correspondence Address: MEYERTONS, HOOD, KIVLIN, KOWERT & (57) ABSTRACT GOETZEL, P.C. Provided in some embodiments is a device suitable for treat P.O. BOX 398 ing an eye that includes a housing and a plurality offins. The AUSTIN, TX 78767-0398 (US) housing includes a base and a rim coupled to the perimeter of the base. The base and the rim at least partially define a cavity (21) Appl. No.: 12/252,136 in the housing, and the cavity is configured to accept one or more radiation seeds. The plurality of fins at least partially (22) Filed: Oct. 15, 2008 reside within or proximate the cavity of the housing. At least a portion of the fins are configured such that radiation emitted Related U.S. Application Data from one or more radiation seeds positioned in the cavity is (60) Provisional application No. 60/980,079, filed on Oct. substantially directed toward a center portion of the eye dur 15, 2007. ing use. SClera ChOroid Patent Application Publication Jun. 18, 2009 Sheet 1 of 8 US 2009/O156881 A1 C-H > O wis w CN Sa CNwas O C v N. l e CD VN sU O S & U wal w- F S S wis,N ws Patent Application Publication Jun.
    [Show full text]
  • Comparison of Retinoblastoma Reduction for Chemotherapy Vs External Beam Radiotherapy
    CLINICAL SCIENCES Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy Daniel A. Sussman, MD; Erika Escalona-Benz, MD; Matthew S. Benz, MD; Brandy C. Hayden, BS; William Feuer, MS; Nicole Cicciarelli; Stuart Toledano, MD; Arnold Markoe, MD; Timothy G. Murray, MD Objective: To determine the time course and extent of Results: Twenty-six eyes of 26 patients were evaluated tumor reduction associated with systemic chemo- for tumor response; 18 patients were treated with sys- therapy or external beam radiotherapy (EBRT) in the treat- temic chemotherapy and 8 patients were treated with ment of advanced intraocular retinoblastoma. EBRT. Median follow-up was 36 months. A mean 68% reduction in tumor volume occurred after 1 cycle of che- Methods: Retrospective review of children with Reese- motherapy compared with a 12% reduction at a similar Ellsworth stages IV and V retinoblastoma undergoing pri- time point (1 month) after initiation of EBRT (PϽ.004). mary globe-conserving therapy with either systemic che- There was no statistically significant difference in tu- moreduction or EBRT. Study variables were recorded at mor volume reduction between treatment modalities at baseline, at monthly intervals for the first 6 months, and the 12-month follow-up visit. Both systemic chemore- at 12 months after the initiation of treatment. Tumor vol- duction and EBRT achieved 100% globe conservation and umes were calculated using basal area and height values 100% patient survival in this series. determined by ultrasonography, physical examination, and fundus photographic review. Conclusions: Retinoblastoma reduction exhibits a dif- ferential time course based on the applied primary treat- Main Outcome Measures: Outcome measures in- ment.
    [Show full text]
  • PATIENTS • Guide • Heal
    Final Program ASTRO 55TH ANNUAL MEETING Meeting Dates: September 22-25, 2013 • Exhibit Dates: September 22-24, 2013 • Georgia World Congress Center • Atlanta HopePATIENTS • Guide • Heal Download ASTROmobile - The offi cial meeting app. See 17 page for details. ANNUAL MEETING SCIENCE BASED, PATIENT DRIVEN www.astro.org/annualmeeting #ASTRO13 ROOM SERVICE NOW AVAILABLE Medical centers that never considered proton therapy accessible are now installing single-room configurations of the MEVION S250™ system. Thanks to a radically smaller footprint, lower capital outlay, reduced operating costs, and complete system integration, advanced proton therapy is now available at the press of a button. ™ Welcome to the world of High Energy Cancer Care ... for everyone. Visit us at ASTRO 2013 Booth #1253 mevion.com LAD130401 Final Program ASTRO 55TH ANNUAL MEETING Meeting Dates: September 22-25, 2013 • Exhibit Dates: September 22-24, 2013 • Georgia World Congress Center • Atlanta HopePATIENTS • Guide • Heal Download ASTROmobile - The offi cial meeting app. See 17 page for details. HELD IN CONJUNCTION WITH: AMERICAN SOCIETY OF RADIOLOGIC TECHNOLOGISTS (ASRT) ANNUAL MEETING ASSOCIATION OF RESIDENTS IN RADIATION ONCOLOGY (ARRO) SCIENCE BASED, PATIENT DRIVEN SOCIETY FOR RADIATION ONCOLOGY ADMINISTRATORS (SROA) www.astro.org/annualmeeting #ASTRO13 Welcome TO THE 55TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY “Patients: Hope, Guide, Heal” Dear Colleagues, On behalf of the American Society for Radiation Oncology, I would like to welcome you to ASTRO’s 55th Annual Meeting. We have developed an exciting program that will provide many opportunities for exchanging scientifi c information as well as professional networking. The theme this year is “Patients: Hope, Guide, Heal.” Given all of the changes we are facing in health care, I feel that it is extremely important to keep our focus on our patients and the best care we can provide them.
    [Show full text]
  • Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— an Update
    Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— An Update Program Directors Patricia Chévez-Barrios MD and Dan S Gombos MD In conjunction with the American Association of Ophthalmic Oncologists and Pathologists McCormick Place Chicago, Illinois Saturday, Oct. 27, 2018 Presented by: The American Academy of Ophthalmology 2018 Ocular Oncology and Pathology Subspecialty Day Advisory Committee Staff Planning Group Daniel S Durrie MD Melanie R Rafaty CMP DES, Director, Patricia Chévez-Barrios MD Associate Secretary Scientific Meetings Program Director Julia A Haller MD Ann L’Estrange, Subspecialty Day Manager Dan S Gombos MD Michael S Lee MD Carolyn Little, Presenter Coordinator Program Director Francis S Mah MD Debra Rosencrance CMP CAE, Vice R Michael Siatkowski MD President, Meetings & Exhibits Former Program Directors Kuldev Singh MD MPH Patricia Heinicke Jr, Copy Editor 2016 Carol L Shields MD Mark Ong, Designer Maria M Aaron MD Gina Comaduran, Cover Designer Patricia Chévez-Barrios MD Secretary for Annual Meeting 2014 Hans E Grossniklaus MD Arun D Singh MD ©2018 American Academy of Ophthalmology. All rights reserved. No portion may be reproduced without express written consent of the American Academy of Ophthalmology. ii Planning Group 2018 Subspecialty Day | Ocular Oncology & Pathology 2018 Ocular Oncology and Pathology Planning Group On behalf of the American Academy of Ophthalmology and the American Association of Ophthalmic Oncologists and Pathologists, it is our pleasure to welcome you to Chicago and
    [Show full text]
  • Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells
    In Vitro Targeting of NG2 Antigen by 213Bi-9.2.27 ␣-Immunoconjugate Induces Cytotoxicity in Human Uveal Melanoma Cells Yong Li,1,2 Jian Wang,1,3 Syed M. Abbas Rizvi,1 Martine J. Jager,4 Robert M. Conway,2 Francis A. Billson,2 Barry J. Allen,1,2,3 and Michele C. Madigan2 PURPOSE. To examine uveal melanoma cell lines for the expres- mately 95% of all uveal melanomas. Primary uveal melanomas sion of human melanoma proteoglycan (NG2) using monoclo- may be treated successfully with enucleation, local tumor re- nal antibody (mAb) 9.2.27 and subsequently to assess the in section, laser photocoagulation, plaque radiotherapy, proton vitro specificity and cytotoxicity of mAb 9.2.27 conjugated to beam therapy, or combinations of therapies.1–6 Earlier studies 213 213 the ␣-particle–emitting radioisotope bismuth ( Bi-9.2.27) found minimal benefits using intravenous chemotherapy or for uveal melanoma cells. immunotherapy for primary and metastatic uveal melanoma, METHODS. Immunocytochemistry and flow cytometry were though some success with these modalities has been reported used to examine OCM-1, OCM-3, OCM-8, OMM-1, Mel202 and recently.6–9 Proton beam therapy or local plaque therapy gen- 92–1 melanoma cell lines for NG2 expression. Melanoma cells erally produces good clinical responses.10 However, radiation- were treated with test (213Bi-9.2.27) or control (213Bi-A2) ␣-im- associated morbidity remains a problem and usually involves munoconjugates (AICs). The specific cytotoxicity of 213Bi- long-term visual complications. Most patients with uveal mel- 9.2.27 AIC was evaluated using an MTS (3-(4,5-dimethylthiazol- anoma display no detectable evidence of metastases at the time 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, of diagnosis; however, within 5 years of enucleation, meta- inner salt) assay.
    [Show full text]